Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8575758 | 0.84 | CTSD (0.57) | PDE7AALDH1A1MAPTCTSDHTT | |
| SCHEMBL13240120 | 0.84 | RECQL (0.65) | RECQLALDH1A1MAPTLMNAPOLB | |
| SCHEMBL975117 | 0.80 | ALDH1A1 (0.68) | ALDH1A1MAPTCTSDHTTTDP1 | |
| SCHEMBL9540049 | 0.80 | RECQL (0.79) | RECQLALDH1A1TDP1FADS1 | |
| SCHEMBL25413293 | 0.79 | VCAM1 (0.57) | ALDH1A1MAPTLMNAPOLBHTT | |
| SCHEMBL31366649 | 0.79 | VCAM1 (0.57) | ALDH1A1MAPTLMNAPOLBHTT | |
| SCHEMBL11295994 | 0.78 | PHGDH (0.57) | ALDH1A1MAPTCTSDPOLB | |
| Methylamine SCHEMBL27483022 | 0.78 | MAPK1 (0.54) | ALDH1A1LMNAPOLBHTT | |
| SCHEMBL29516764 | 0.78 | RECQL (1.00) | RECQLALDH1A1MAPTLMNAPOLB | |
| SCHEMBL333313 | 0.78 | RECQL (1.00) | RECQLALDH1A1MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1213332-B1 | Recording liquid, ink jet recording method and recording equipment using the same | RICOH KK (JP) | 2004-04-28 | — | — | EP | disclosed |
| US-20040039001-A1 | 2-guanidino-4-aryl-quinazoline | MERCK PATENT GMH (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1315704-A1 | 2-GUANIDINO-4-ARYL-QUINAZOLINE | MERCK PATENT GmbH (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-1213332-A1 | Recording liquid, ink jet recording method and recording equipment using the same | Ricoh Company, Ltd. (JP) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002020496-A1 | 2-GUANIDINO-4-ARYL-QUINAZOLINE | MERCK PATENT GMBH (DE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039001-A1 | 2-guanidino-4-aryl-quinazoline | NHERF1, SLC9A3, SLC9A5 | RECQL 459/4885PDE7A 438/4885ALDH1A1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.